Eli Lilly & Co.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B |
| Zyprexa | — | $0 | $0 | $0 | $0 | $0 | $0 | $343.3M |
| Cialis | — | $0 | $0 | $0 | $0 | $810.0M | $622.1M | $890.6M |
| Alimta | — | $0 | $0 | $226.7M | $927.8M | $1.23B | $1.25B | $1.69B |
| Humalog | — | $1.10B | $1.28B | $1.63B | $2.06B | $2.45B | $2.63B | $2.82B |
| Humulin | — | $541.2M | $627.5M | $796.8M | $1.02B | $1.22B | $1.23B | $1.29B |
| Gemzar | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Evista | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Forteo | — | $0 | $466.8M | $580.4M | $612.9M | $802.2M | $1.05B | $1.41B |
| Strattera | — | $0 | $0 | $0 | $0 | $790.0M | $816.0M | $698.8M |
| Symbyax | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Erbitux | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Byetta | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Trad jenta | — | $0 | $0 | $0 | $0 | $0 | $478.2M | $503.7M |
| Effient | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Jardiance | — | $3.81B | $3.23B | $2.57B | $2.06B | $1.49B | $1.24B | $944.8M |
| Trulicity | — | $5.82B | $6.23B | $7.13B | $7.44B | $6.47B | $5.05B | $4.13B |
| Taltz | — | $3.41B | $3.10B | $2.76B | $2.48B | $2.21B | $1.79B | $1.37B |
| Olumiant | — | $142.3M | $154.2M | $168.5M | $179.2M | $111.4M | $88.4M | $42.4M |
| Verzenio | — | $6.21B | $5.08B | $3.86B | $2.01B | $1.35B | $912.7M | $580.4M |
| Emgality | — | $821.6M | $746.5M | $678.4M | $650.9M | $550.8M | $383.9M | $162.5M |
| Tyvyt | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cyramza | — | $1.12B | $1.08B | $1.01B | $971.0M | $1.03B | $883.3M | $925.2M |
| Baqsimi | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retevmo | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Bebtelovimab | — | $0 | $0 | $0 | $1.20B | $2.24B | $810.2M | $0 |
| Mounjaro | — | $17.53B | $11.54B | $5.16B | $482.5M | $0 | $0 | $0 |
| Jaypirca | — | $481.0M | $320.0M | $128.0M | $0 | $0 | $0 | $0 |
| Zepbound | — | $10.21B | $3.03B | $175.8M | $0 | $0 | $0 | $0 |
| Omvoh | — | $112.4M | $0 | $0 | $0 | $0 | $0 | $0 |
| Ebglyss | — | $98.6M | $0 | $0 | $0 | $0 | $0 | $0 |
| Kisunla | — | $85.2M | $0 | $0 | $0 | $0 | $0 | $0 |
| Animal Health | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Collaboration and Other Revenue | — | $1.65B | $1.30B | $1.09B | $511.2M | $378.1M | $309.8M | $248.5M |
| Other Pharmaceutical Products | — | $12.03B | $6.85B | $6.15B | $5.04B | $4.97B | $5.13B | $4.48B |
| Cost of Revenue | — | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B |
| Gross Profit | — | $54.13B | $36.62B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B |
| Gross Margin | — | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $7.19B | $6.93B | $5.98B | $5.60B |
| SG&A Expense | — | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B | $6.21B |
| Operating Income | — | $25.73B | $12.68B | $7.04B | $7.14B | $6.50B | $7.59B | $5.67B |
| Operating Margin | — | 39.5% | 28.2% | 20.6% | 25.0% | 22.9% | 30.9% | 25.4% |
| Interest Expense | — | — | — | $485.9M | $331.6M | $339.8M | $359.6M | $400.6M |
| Pretax Income | — | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B |
| Income Tax Expense | — | $5.09B | $2.09B | $1.31B | $561.6M | $573.8M | $1.04B | $628.0M |
| Net Income | — | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B |
| Net Margin | — | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% |
| EPS (Basic) | — | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 | $8.93 |
| EPS (Diluted) | — | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 |
| Shares Outstanding (Basic) | 943.4M | 897.3M | 900.6M | 900.2M | 901.7M | 907.0M | 907.6M | 931.1M |
| Shares Outstanding (Diluted) | 943.4M | 899.3M | 904.1M | 903.3M | 904.6M | 911.7M | 912.5M | 935.7M |
| Dividends Per Share | — | $6.23 | $5.40 | $4.69 | $4.07 | $3.53 | $3.07 | $2.68 |